SUBSCRIBE
SUBSCRIBE

Gilead Sciences, Inc.

NEWS
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Biotech Beach
SoCal’s Kite Pharma, Inc. Talks With Insurers to Avoid Gilead Sciences, Inc. Price War
January 15, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Policy
Gilead’s India Patent Roadblock May Spur More Sovaldi Copies
January 15, 2015
 · 
2 min read
J.P. Morgan: Bluebird Bio Trading Near Historic Highs
Business
J.P. Morgan: Gilead Sciences, Inc. President Says 48% of Revenue Comes From Hep C Drugs
January 13, 2015
 · 
1 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Gilead Sciences, Inc. Throws Another Punch at AbbVie by Striking Deal With Anthem, Inc.
January 9, 2015
 · 
2 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Deals
Gilead Sciences, Inc. Snaps Up Liver Disease Treatment from Phenex Pharmaceuticals AG in $470 Million Deal
January 6, 2015
 · 
2 min read
Biogen Idec Alzheimer's Drug Aducanumab Exceeds Expectations
Biotech Bay
Gilead Sciences, Inc. Fights Back as CVS Will Exclusively Cover Hepatitis C Drug Harvoni
January 5, 2015
 · 
2 min read
Mylan Inc., Theravance, Inc. Partner Up for $265 Million COPD Pact
Deals
Arrowhead Research Corporation Soars on Rumor of Gilead Sciences, Inc.'s Interest
December 31, 2014
 · 
2 min read
Share Buybacks Could Save Gilead After Turbulent Two Weeks, Says Citi
Biotech Bay
Share Buybacks Could Save Gilead Sciences, Inc. After Turbulent Two Weeks, Says Citi
December 29, 2014
 · 
1 min read
Astellas Pharma, Proteostasis Therapeutics Forge $1.2 Billion Genetic Disease Drug Development Pact
Business
Gilead Sciences, Inc., Johnson & Johnson Expand Existing HIV R&D Pact
December 29, 2014
 · 
2 min read
Load More
  • 2025 BPTW Badge - RBG.png
  • 2024 Best Places to Work
  • 2023 Best Places to Work
  • 2022 Best Places to Work
JOBS
IN THE PRESS
Drug Development
Gilead Sciences, Inc.'s Respiratory Syncytial Virus (RSV) Drug GS-5806 Wows In Phase 2 Trial
May 21, 2014
 · 
5 min read
Biotech Bay
Gilead Sciences, Inc. To Present At The 2014 UBS Healthcare Conference On Tuesday, May 20
May 20, 2014
 · 
1 min read
Biotech Bay
Gilead Sciences, Inc. To Present At The Bank of America Merrill Lynch 2014 Health Care Conference On Wednesday, May 14
May 14, 2014
 · 
1 min read
Drug Development
Gilead Sciences, Inc. Announces Phase 1 Data For Investigational Therapy, GS-6615, In Patients With Long QT-3 Syndrome
May 12, 2014
 · 
1 min read
Drug Development
Gilead Sciences, Inc. Announces Results From Phase 2 Study Showing Reduction In Atrial Fibrillation Burden With The Investigational Combination Of Ranolazine And Low-Dose Dronedarone
May 12, 2014
 · 
1 min read
Business
Gilead Sciences, Inc. Shareholders Decimate Plan To Tie CEO Compensation To Drug Access
May 8, 2014
 · 
1 min read
Biotech Bay
Gilead Sciences, Inc. Will Buy Back Another $5 Billion Of Shares
May 7, 2014
 · 
2 min read
Genetown
Gilead Sciences, Inc.'s Solvadi Strikes Again: $1,000 A Pill Rattles Medicaid Programs
April 29, 2014
 · 
1 min read
Business
Solvaldi Too Expensive? Not To Patients—Gilead Sciences, Inc. Profit Triples On Strong Hep C Drug Sales
April 23, 2014
 · 
1 min read
Business
Gilead Sciences, Inc. Announces First Quarter 2014 Financial Results
April 23, 2014
 · 
1 min read
Load More